Among the antibodies for DR4 or DR5, conatumumab (AMG655, antibody for DR5) [11] and tigatuzumab (CS-1008/TRA-8, antibody for DR5) [12] are being tested for treatment of pancreatic cancers (http://Clinicaltrials.gov). Here, TNFRSF10A is linked to pancreatic neoplasm.